InvestorsHub Logo
Followers 95
Posts 4214
Boards Moderated 1
Alias Born 11/05/2014

Re: None

Monday, 12/04/2023 4:06:36 PM

Monday, December 04, 2023 4:06:36 PM

Post# of 171
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
PR Newswire
Data to be announced in a premarket press release followed by a conference call at 8:30 am ET
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NRSN News